Tranexamic acid

Generic Name: Tranexamic acid

Brand Names: Cyklokapron, Lysteda

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₅NO_₂

CAS Number: 1197-18-8

Unique Ingredient Identifier: 6T84R30KC1

Background: Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication: Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.

Associated Conditions: Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)

Associated Therapies: -

Clinical Trials

Tranexamic Acid in Preventing Postpartum Hemorrhage in High Risk Pregnancies During Elective Cesarean Section

Phase 2

Completed

Conditions: Postpartum Hemorrhage

Interventions: Drug: Tranexamic Acid

First Posted Date: 2017-11-24

Last Posted Date: 2017-11-27

Lead Sponsor: Mansoura University

Target Recruit Count: 140

Registration Number: NCT03351686

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

Phase 4

Completed

Conditions: Heavy Menstrual Bleeding
Menorrhagia
Uterine Fibroids

Interventions: Drug: Levonorgestrel IUS
Drug: Tranexamic Acid

First Posted Date: 2017-10-23

Last Posted Date: 2021-12-08

Lead Sponsor: Shannon K. Laughlin-Tommaso

Target Recruit Count: 18

Registration Number: NCT03317795

Locations: 🇺🇸
Mayo Clinic in Jacksonville, Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States

Reducing Blood Loss Using Tisseel in TKA

Phase 4

Conditions: Total Blood Loss

Interventions: Drug: Tisseel
Drug: Tranexamic Acid

First Posted Date: 2017-10-16

Last Posted Date: 2017-10-16

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 100

Registration Number: NCT03310060

Prevention of Postpartum Hemorrhage With Tranexamic Acid

Phase 2

Active, not recruiting

Conditions: Postpartum Hemorrhage

Interventions: Drug: Tranexamic Acid

First Posted Date: 2017-09-19

Last Posted Date: 2022-10-19

Lead Sponsor: George Washington University

Target Recruit Count: 30

Registration Number: NCT03287336

Locations: 🇺🇸
James Slota, Washington, District of Columbia, United States

Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients

Phase 4

Completed

Conditions: Hip Fractures
Anemia

Interventions: Drug: Tranexamic Acid
Drug: Saline Solution

First Posted Date: 2017-07-07

Last Posted Date: 2022-04-07

Lead Sponsor: Alejandro Lizaur-Utrilla, PhD, MD

Target Recruit Count: 129

Registration Number: NCT03211286

Locations: 🇪🇸
Hospital Universitario de Elda, Elda, Alicante, Spain
🇪🇸
Elda University Hospital, Elda, Alicante, Spain

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

Early Phase 1

Recruiting

Conditions: Pelvic Mass

Interventions: Procedure: Hemipelvectomy
Drug: Tranexamic Acid

First Posted Date: 2017-04-25

Last Posted Date: 2024-02-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT03128866

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Topical and Systemic Tranexemic Acid on Bleeding During Ear Exploration Surgery

Phase 2

Conditions: Intraoperative Bleeding

Interventions: Drug: Tranexamic Acid
Drug: Adrenalin

First Posted Date: 2017-04-13

Last Posted Date: 2017-04-13

Lead Sponsor: Assiut University

Target Recruit Count: 90

Registration Number: NCT03112135

Locations: 🇪🇬
Egypt, Asyut, Egypt

TRANexamic Acid to Reduce Bleeding in BURN Surgery

Phase 4

Completed

Conditions: Tranexamic Acid
Burns
Wounds and Injuries
Surgery

Interventions: Drug: Tranexamic Acid
Drug: Placebo

First Posted Date: 2017-04-13

Last Posted Date: 2024-04-04

Lead Sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon

Target Recruit Count: 121

Registration Number: NCT03113253

Locations: 🇫🇷
Service de réanimation des brûlés de Mercy (CHR Metz-Thionville), Ars-Laquenexy, France
🇫🇷
Centre Commun de Traitement des Brûlés - Hôpital Edouard Herriot, Lyon, France
🇫🇷
Centre des brûlés inter-régional Méditerranée - Hôpital de la Conception, Marseille, France

and more 1 locations

Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients

Phase 4

Conditions: Knee Osteoarthritis

Interventions: Drug: Tranexamic Acid

First Posted Date: 2017-04-12

Last Posted Date: 2019-01-08

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 144

Registration Number: NCT03109652

Locations: 🇰🇷
Seoul National University Boramae Medical Center, Seoul, Dongjak Gu, Korea, Republic of

Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery

Phase 3

Terminated

Conditions: Intra-Operative Injury - Other
Post Operative Hemorrhage
Tranexamic Acid

Interventions: Drug: Placebo
Drug: tranexamic acid

First Posted Date: 2017-03-21

Last Posted Date: 2023-04-19

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 152

Registration Number: NCT03085394

Locations: 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy